LEXEO Therapeutics
34 articles about LEXEO Therapeutics
-
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
4/16/2024
Lexeo Therapeutics, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LX2006, the company’s AAVrh.10hFXN-based gene therapy candidate for the treatment of Friedreich’s ataxia (FA) cardiomyopathy.
-
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
3/13/2024
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, announced the closing of its previously announced private placement.
-
Separate challenges exist for companies developing gene therapies for rare and common cardiovascular conditions, experts told BioSpace.
-
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
3/11/2024
Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today reported fourth quarter and full year 2023 financial results and provided operational highlights.
-
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
3/11/2024
Lexeo Therapeutics, Inc. announced it has entered into a common stock purchase agreement with a select group of institutional and healthcare accredited investors to issue and sell an aggregate of 6,278,905 shares of its common stock at a price of $15.13 per share, in a private placement.
-
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
2/5/2024
Lexeo Therapeutics, Inc. (Nasdaq: LXEO) today announced new executive appointments to lead the evolution of the company’s pipeline into late-stage clinical development.
-
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Lexeo Therapeutics, Inc. (Nasdaq: LXEO) today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 8:15 AM PT in San Francisco, California.
-
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
12/18/2023
Lexeo Therapeutics, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation and Orphan Drug designation to LX2020.
-
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
12/11/2023
Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today reported third quarter 2023 financial results and provided operational highlights.
-
The New York-based genetic medicine company, which expects gross proceeds of approximately $100 million, joins a small group of biotechs that have launched initial public offerings this year.
-
Lexeo Therapeutics Announces Pricing of Initial Public Offering - November 03, 2023
11/3/2023
Lexeo Therapeutics, Inc. announced the pricing of its initial public offering of 9,090,910 shares of common stock at a price to the public of $11.00 per share.
-
Despite a sharp downturn in initial public offering activity, New York-based gene therapy company Lexeo Therapeutics and French biotech Abivax are seeking funding for their lead candidate programs.
-
LEXEO Therapeutics Announces Strategic Investment from Sarepta Therapeutics to Support Development of LEXEO’s Cardiovascular Gene Therapies
8/28/2023
LEXEO Therapeutics, a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined sub-group of Alzheimer’s disease, announced a strategic investment from Sarepta Therapeutics, Inc. to support the advancement of LEXEO’s adeno-associated virus gene therapy programs.
-
LEXEO Therapeutics Announces FDA Clearance of IND for LX2020, an AAV-based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy
8/1/2023
LEXEO Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for LX2020. LX2020 is an AAVrh10-based gene therapy candidate designed to intravenously deliver a functional PKP2 gene to cardiac muscle for the treatment of Arrhythmogenic Cardiomyopathy (ACM) caused by variants in the PKP2 gene (PKP2-ACM).
-
LEXEO Therapeutics Announces Completion of First Cohort and Dosing in Second Cohort in SUNRISE-FA, a Phase 1/2 Clinical Trial of LX2006 for the Treatment of Friedreich’s Ataxia Cardiomyopathy
6/13/2023
LEXEO Therapeutics announced the completion of the first dose cohort and the dosing of the first patient in the second dose cohort in SUNRISE-FA, a Phase 1/2 clinical trial of LX2006 in patients with Friedreich’s ataxia cardiomyopathy.
-
LEXEO Therapeutics Announces Data Presentations at the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
5/2/2023
LEXEO Therapeutics announced today that new data supporting its cardiac and neurological gene therapy programs will be presented at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 16-20, 2023.
-
LEXEO Therapeutics Appoints Micah Zajic as Chief Financial Officer and Paula H. J. Cholmondeley as Board of Directors Audit Committee Chair
1/5/2023
LEXEO Therapeutics, Inc. today announced the expansion of its leadership team, with the appointment of Micah Zajic as Chief Financial Officer and Paula H.J. Cholmondeley to its Board of Directors as Audit Committee Chair.
-
LEXEO Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
LEXEO Therapeutics, Inc. today announced that R. Nolan Townsend, Chief Executive Officer of LEXEO Therapeutics, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 10:30 AM PT.
-
Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research
11/7/2022
Cerveau Technologies, Inc. announced a license agreement with LEXEO Therapeutics, Inc., which will enable LEXEO to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.
-
LEXEO Therapeutics Bolsters Cardiac Gene Therapy Leadership with New Executive Appointment and Formation of Scientific Advisory Board
11/2/2022
LEXEO Therapeutics, Inc. today announced a new executive appointment, as well as the development of a Scientific Advisory Board.